June 5, 2022New England Journal of Medicine1,219 citationsOpen Access
Teclistamab in Relapsed or Refractory Multiple Myeloma
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Cite This Study
Moreau et al. (2022) studied this question.